Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry

Abstract Introduction Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germ...

Full description

Bibliographic Details
Main Authors: Uwe Zeymer, Christiane Lober, Andreas Wolf, Frank Richard, Heinrich Schäfer, Jens Taggeselle, Hans-Joachim Kabitz, Roland Prondzinsky, Tim Süselbeck, the APAF-Investigators
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Cardiology and Therapy
Subjects:
Atrial fibrillation
Apixaban
Prospective registry
Persistence
Online Access:https://doi.org/10.1007/s40119-020-00188-1

Internet

https://doi.org/10.1007/s40119-020-00188-1

Similar Items